Simplify Asset Management Inc. Buys Shares of 20,520 Insmed Incorporated (NASDAQ:INSM)

Simplify Asset Management Inc. acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 20,520 shares of the biopharmaceutical company's stock, valued at approximately $1,417,000.

Other institutional investors also recently modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its holdings in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the period. Spire Wealth Management acquired a new position in Insmed in the 4th quarter valued at about $47,000. Smartleaf Asset Management LLC raised its holdings in Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 411 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Insmed during the fourth quarter worth approximately $86,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. UBS Group lifted their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 6,172 shares of the business's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the sale, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. The trade was a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 550,957 shares of company stock worth $42,992,528. Corporate insiders own 4.60% of the company's stock.

Insmed Price Performance

Insmed stock traded up $1.12 during midday trading on Thursday, reaching $77.69. The company's stock had a trading volume of 1,139,707 shares, compared to its average volume of 2,179,246. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market cap of $14.06 billion, a PE ratio of -13.90 and a beta of 1.28. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The business has a 50-day moving average price of $78.07 and a 200-day moving average price of $73.93.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.